Imunon’s (IMNN) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Imunon (NASDAQ:IMNN) in a research note issued to investors on Monday,Benzinga reports. They currently have a $29.00 target price on the stock.

Other research analysts also recently issued reports about the company. HC Wainwright cut their price target on Imunon from $14.00 to $12.00 and set a “buy” rating for the company in a report on Monday, November 11th. EF Hutton Acquisition Co. I upgraded Imunon to a “strong-buy” rating in a research note on Monday, September 23rd.

Imunon Price Performance

Shares of NASDAQ IMNN opened at $0.86 on Monday. The company has a 50-day simple moving average of $0.93 and a 200-day simple moving average of $1.14. The company has a market cap of $12.41 million, a PE ratio of -0.45 and a beta of 2.14. Imunon has a 12 month low of $0.48 and a 12 month high of $3.65.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.